WO2021006839A1 - Method for obtaining solid plasma as a filling material - Google Patents

Method for obtaining solid plasma as a filling material Download PDF

Info

Publication number
WO2021006839A1
WO2021006839A1 PCT/TR2020/050560 TR2020050560W WO2021006839A1 WO 2021006839 A1 WO2021006839 A1 WO 2021006839A1 TR 2020050560 W TR2020050560 W TR 2020050560W WO 2021006839 A1 WO2021006839 A1 WO 2021006839A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasma
thrombocyte
leukocytes
filling material
obtaining
Prior art date
Application number
PCT/TR2020/050560
Other languages
French (fr)
Inventor
Mesut KARAHAN
Original Assignee
Gazi̇ Endüstri̇ Anoni̇m Şi̇rketi̇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gazi̇ Endüstri̇ Anoni̇m Şi̇rketi̇ filed Critical Gazi̇ Endüstri̇ Anoni̇m Şi̇rketi̇
Publication of WO2021006839A1 publication Critical patent/WO2021006839A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0281Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/75General characteristics of the apparatus with filters

Definitions

  • the invention relates to a method for obtaining solid plasma which is a completely organic filling material composed of individual’s own blood cells and plasma instead of chemical filling materials used in medical aesthetics.
  • Aesthetics surgery is a surgical branch that is activated in cases where people can be born with some congenital body anomalies or when a condition like illness, accident, old age can cause disruption in their body shape.
  • Aesthetics surgery also known as plactic surgery is a branch of medicine that repairs tissue and organ disorders in different parts of the body. In plastic surgery operations, tissues are reshaped according to the current disorder and the person is tried to be given the best appearance.
  • Hyaluronic acid which is used in the present art, is actually a chemical filler and since it is obtained from chemicals, it can lead to very severe complications and allergies that take 48 hours after application to the human body and regions thereof (lips, cheeks, under eyes, etc.). Also, very high material costs are paid for the amount of 1 ml of Hyaluronic acid, which consists of the mentioned chemical substances, according to the region to be applied.
  • Patent application TR 2006/02727 belonging to the state of art relates to the removal of fibroblasts, which are a human skin cell, from individuals and culturing thereof in a laboratory environment (autologous cultured fibroblasts) and back injection of the product prepared by placing these cells in a carrier medium consisting of hyaluronic acid, which is also an existing substance in human skin for solving the problems emerging as a result of treatment or aging process in health industry.
  • cultured fibroblasts are injected into the human body together with hyaluronic acid and it does not solve the problem of usage with chemicals.
  • this invention relates to activation and purification in prp (platalet rich plasma) process which is required for treatment (mostly used in physiotherapy, orthopedics, plastic surgery, skin, hair transplantation) method which is developed for medical usage and used in the regions where cell renewal is desired.
  • This invention discloses obtaining a product which is ready to use as a filling material although it does not solve the problem of dissociating the plasma and blood cells effectively during prp (platalet rich plasma) process.
  • Purpose of the invention is to perform a method of obtaining a solid plasma which provides that instead of chemical substances such as hyaluronic acid, solid plasma completely obtained from human blood is used as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.
  • Another purpose of the invention is to perform a method of obtaining solid plasma solving the problems of whole complication and non-adaptation that may arise as a result of obtaining the filling material to be injected into the body of the user from the human’s own blood.
  • Another purpose of the invention is to perform a method of obtaining solid plasma enabling the usage of the filling material as solid plasma preventing the cases which lead to a variety of complications and allergy lasting 48 hours which may arise as a result of using chemical substances such as hyaluronic acid as filling material.
  • Another purpose of the invention is to eliminate high costs paid for the amount of 1 ml of the chemical filling materials used according to the application area.
  • Another object of the invention is to perform a method of obtaining solid plasma which will enable the usage of the materials to be used as medical aesthetics material not only to the face and neck region but also to the remaining parts of the body by means of the developing technology.
  • Figure 1 is a schematic view of the method phases of obtaining the inventive solid plasma and devices used.
  • the invention is a method of obtaining solid plasma which is completely obtained from human blood instead of chemical substances for using as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.
  • Inventive method of obtaining solid plasma (100) comprises the following process steps:
  • the blood sample (2) consists of cells (6) and a fluid called plasma (3).
  • Cells (erythrocytes) (red blood cells) (6) are the leukocytes (white blood cells) (7) and the platelets (4).
  • Red blood cells (6) make up more than 99% of the cells.
  • Red blood cells (6) are oxygen-carrying cells of the blood.
  • Leukocytes (7) are cells that protect the body against infections and cancer. Platelets (4) take part in blood clotting.
  • the blood sample (2) placed in the glass blood collection tube (1 ) is centrifuged and the red blood cells (6) and leukocytes (7) are dissociated from the plasma (3) and platelets (4). Since the red blood cells (6) and leukocytes (7) are heavier, while they deposit in the bottom, the lighter thrombocyte (4) and plasma (3) remain on top.
  • Plasma (3) is the liquid part of the blood sample (2), it consists of a large number of organic and inorganic substances dissolved in water. The most important of these substances are proteins. Proteins make up about 7% of the total weight of the plasma. Plasma proteins are divided into three main groups. These are albumin, globulins and fibrinogen. The proteins and useful cells in the plasma are directly effective in gaining the healthy tissues and elasticity that the human body loses with aging.
  • the blood sample (2) is centrifuged at 1 100 RPM for 9 minutes (1 ) in small glass blood collection tubes called "micro pipette" inside of which is plastered with heparin.
  • micro pipette small glass blood collection tubes
  • erythrocytes that is, red blood cells (6)
  • platelets (4) in the form of a very thin layer are present, at the uppermost clear straw yellow-white liquid called plasma (3) is collected
  • the cells required for the solid plasma are filtered by performing dissociation process to the whole blood sample (2).
  • the red cells (6), leukocytes (7) which are trapped under the filter (5) and the platelets (4) and the plasma (3) that is, the useful cells which are on the upper part of the filter (5) are dissociated.
  • the filter (5) filtering the cells required for the solid plasma by dissociating the whole blood sample (2) is a polyester micro filter.
  • Incubation device (8) is used in the process of transforming the resulting plasma (3) and the liquid consisting of useful cells into solid plasma filling (9). Dissociated plasma (3) and platelet (4) are mixed and placed in the incubation device (8) and hold therein for 5 minutes at 70 e C, 7 minutes at 90 e C and 5 minutes at 5 e C.
  • the plasma (3) taken from said incubation device (8) is solid plasma filling (9) to be used as filling material.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention is a method of obtaining a solid plasma (100) for use as a filling material in anti-aging applications in medical aesthetics field and in filling method applied to restore the shape of the deformed area as a result of deformation occurring in the body, which is completely obtained from human blood instead of chemical substances, in which blood samples (2) taken into the glass blood collection tubes (1), are dissociated into plasma (3), thrombocyte (4), red blood cells (6) and leukocytes (7) by centrifugation (101), wherein the method comprises the process steps of after performing the said dissociation process with centrifugation (101), dissociating the plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of a filter (5) (102), placing the dissociatied plasma (3) and thrombocyte (4) in the incubation device (8) by mixing, holding it at the determined temperature and time intervals, and holding it until the time expires (104) and as a result of the holding time taking it from the incubation device (8) as ready-to-use solid plasma (9) to be used as filling material.

Description

METHOD FOR OBTAINING SOLID PLASMA AS A FILLING MATERIAL
Technical Field
The invention relates to a method for obtaining solid plasma which is a completely organic filling material composed of individual’s own blood cells and plasma instead of chemical filling materials used in medical aesthetics.
State of the Art
Aesthetics surgery is a surgical branch that is activated in cases where people can be born with some congenital body anomalies or when a condition like illness, accident, old age can cause disruption in their body shape. Aesthetics surgery also known as plactic surgery is a branch of medicine that repairs tissue and organ disorders in different parts of the body. In plastic surgery operations, tissues are reshaped according to the current disorder and the person is tried to be given the best appearance.
Nowadays, aesthetic surgery has made significant progress in applying anti-aging treatments to individuals. Disorders in facial contours and body shapes that people face due to some genetic features or aging can be solved with many different treatment methods with developing technology. The important point in the treatment methods is to give the most natural and healthy appearance to the person.
The face and neck area is the most important regions where medical aesthetic applications are most commonly applied in the human body. Problems such as sagging, wrinkles, distortion of the V-shape of the face, under eye problems, mimic lines are solved by organic fillings injected into the problematic chamber without distorting the shape of the face and neck. The fillings are divided into three as permanent fillings, semi-permanent fillings and non-permanent fillings. Permanent fillings remain in the body for life and are used for rejuvenation as well as deformities caused by deformation. Efficacy time of the semi-permanent fillers vary between 3-5 years. The most preferred filling applications are non-permanent filling applications. The most preferred one in non-permanent fillers is actually a polysaccharide sugar chain (NASHA) known as hyaluronic acid. It is found naturally in human body. The function of the hyaluronic acis naturally present in tissues is to carry and fix the water into the skin The acid, which is synthetic or animal origin, can be easily accepted by the body. This substance has functions such as cell division, providing the slipperiness of the joints and giving tension to the skin. Hyaluronic acid can retain a thousand times more water than its own volume and maintain its shape for a long time where it is injected. It is produced under special laboratory conditions and presented to cosmetic applications. It is metabolized and excreted by the body in an average of 6-12 months. However, Hyaluronic acid, which is used in the present art, is actually a chemical filler and since it is obtained from chemicals, it can lead to very severe complications and allergies that take 48 hours after application to the human body and regions thereof (lips, cheeks, under eyes, etc.). Also, very high material costs are paid for the amount of 1 ml of Hyaluronic acid, which consists of the mentioned chemical substances, according to the region to be applied.
Patent application TR 2006/02727 belonging to the state of art relates to the removal of fibroblasts, which are a human skin cell, from individuals and culturing thereof in a laboratory environment (autologous cultured fibroblasts) and back injection of the product prepared by placing these cells in a carrier medium consisting of hyaluronic acid, which is also an existing substance in human skin for solving the problems emerging as a result of treatment or aging process in health industry. However in said application cultured fibroblasts are injected into the human body together with hyaluronic acid and it does not solve the problem of usage with chemicals.
In another patent application TR 2015/13883 belonging to the state of art, this invention relates to activation and purification in prp (platalet rich plasma) process which is required for treatment (mostly used in physiotherapy, orthopedics, plastic surgery, skin, hair transplantation) method which is developed for medical usage and used in the regions where cell renewal is desired. This invention discloses obtaining a product which is ready to use as a filling material although it does not solve the problem of dissociating the plasma and blood cells effectively during prp (platalet rich plasma) process.
Purpose of the Invention
Purpose of the invention is to perform a method of obtaining a solid plasma which provides that instead of chemical substances such as hyaluronic acid, solid plasma completely obtained from human blood is used as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.
Another purpose of the invention is to perform a method of obtaining solid plasma solving the problems of whole complication and non-adaptation that may arise as a result of obtaining the filling material to be injected into the body of the user from the human’s own blood.
Another purpose of the invention is to perform a method of obtaining solid plasma enabling the usage of the filling material as solid plasma preventing the cases which lead to a variety of complications and allergy lasting 48 hours which may arise as a result of using chemical substances such as hyaluronic acid as filling material.
Another purpose of the invention is to eliminate high costs paid for the amount of 1 ml of the chemical filling materials used according to the application area.
Another object of the invention is to perform a method of obtaining solid plasma which will enable the usage of the materials to be used as medical aesthetics material not only to the face and neck region but also to the remaining parts of the body by means of the developing technology.
Description of Drawings
Figure 1 . is a schematic view of the method phases of obtaining the inventive solid plasma and devices used.
Figure 2. is a schematic view of the process steps of the method of obtaining the inventive solid plasma.
Description of the part references
1.Glass blood collection tube
2. Blood sample
3. Plasma
4. Thrombocyte
5. Filter
6.Red blood cells
7. Leukocytes
8. Incubation device
9. Solid plasma filling
100. Method of obtaining solid plasma
101. subjecting a blood sample (2) taken into the glass blood collection tube (1 ) to the dissociation process by centrifugation
102. upon the dissociation process, dissociating a plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of polyester micro filter (5)
103.destroying the remaining glass blood collection tube (1 ) together with dissociated red blood cells (6) and leukocytes (7) 104. placing the dissociatied plasma (3) and thrombocyte (4) in the incubation device (8) by mixing, holding it at the determined temperature and time intervals and holding it until the time expires
105. at the end of the period, obtaining the solid plasma filling (9)
Drawings are not necessarily drawn according to the scale and details which are not necessary for the understanding of the present invention might be omitted. Additionally, at least significantly identical elements or elements having at least significantly identical functions are shown with the same reference number.
Detailed Description of the Invention
In this detailed description, prefered embodiments of the invention will be only disclosed for the better understanding of the subject and without forming any limiting effect.
The invention is a method of obtaining solid plasma which is completely obtained from human blood instead of chemical substances for using as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.
Inventive method of obtaining solid plasma (100) comprises the following process steps:
- subjecting a blood sample (2) taken into the glass blood collection tube (1 ) to the dissociation process by centrifugation (101 ),
- upon the dissociation process, dissociating a plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of polyester micro filter (5) (102),
- destroying the remaining glass blood collection tube (1 ) together with the dissociated red blood cells (6) and leukocytes (7) (103),
- placing the separated plasma (3) and platelet (4) into the incubation device (8) by mixing and holding at determined temperature intervals and holding it until the time expires (104),
- at the end of the period, obtaining the solid plasma filling (9) (105).
The blood sample (2) consists of cells (6) and a fluid called plasma (3). Cells (erythrocytes) (red blood cells) (6) are the leukocytes (white blood cells) (7) and the platelets (4). Red blood cells (6) make up more than 99% of the cells. Red blood cells (6) are oxygen-carrying cells of the blood. Leukocytes (7) are cells that protect the body against infections and cancer. Platelets (4) take part in blood clotting. The blood sample (2) placed in the glass blood collection tube (1 ) is centrifuged and the red blood cells (6) and leukocytes (7) are dissociated from the plasma (3) and platelets (4). Since the red blood cells (6) and leukocytes (7) are heavier, while they deposit in the bottom, the lighter thrombocyte (4) and plasma (3) remain on top.
Plasma (3) is the liquid part of the blood sample (2), it consists of a large number of organic and inorganic substances dissolved in water. The most important of these substances are proteins. Proteins make up about 7% of the total weight of the plasma. Plasma proteins are divided into three main groups. These are albumin, globulins and fibrinogen. The proteins and useful cells in the plasma are directly effective in gaining the healthy tissues and elasticity that the human body loses with aging.
The blood sample (2) is centrifuged at 1 100 RPM for 9 minutes (1 ) in small glass blood collection tubes called "micro pipette" inside of which is plastered with heparin. At the bottom of these said glass blood collection tubes (1 ), erythrocytes, that is, red blood cells (6), are collected, at the top of this leukocytes (7) and platelets (4) in the form of a very thin layer are present, at the uppermost clear straw yellow-white liquid called plasma (3) is collected
By means of the filter (5), the cells required for the solid plasma are filtered by performing dissociation process to the whole blood sample (2). At the end of the centrifugation process, the red cells (6), leukocytes (7) which are trapped under the filter (5) and the platelets (4) and the plasma (3) that is, the useful cells which are on the upper part of the filter (5) are dissociated.
In the principle application of the invention, the filter (5) filtering the cells required for the solid plasma by dissociating the whole blood sample (2) is a polyester micro filter.
Incubation device (8) is used in the process of transforming the resulting plasma (3) and the liquid consisting of useful cells into solid plasma filling (9). Dissociated plasma (3) and platelet (4) are mixed and placed in the incubation device (8) and hold therein for 5 minutes at 70 eC, 7 minutes at 90 eC and 5 minutes at 5 eC.
The plasma (3) taken from said incubation device (8) is solid plasma filling (9) to be used as filling material.
After passing all stages it is a chemical-free filling material, since it is obtained by an autologous method, ready-to-use solid plasma filling (9) consisting of useful cells and plasma (3) present in human blood.

Claims

1. A method of obtaining a solid plasma (100) in which blood samples (2) taken into the glass blood collection tubes (1 ), are dissociated into plasma (3), thrombocyte (4), red blood cells (6) and leukocytes (7) by centrifugation (101 ) for use as a filling material in anti-aging applications in medical aesthetics field and in filling method applied to restore the shape of the deformed area as a result of deformation occurring in the body, characterized by comprising of the following steps:
i. after performing the dissociation process with centrifugation (101 ), dissociating the plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of a filter (5) (102),
ii. placing the dissociatied plasma (3) and thrombocyte (4) in the incubation device (8) by mixing, holding it at the determined temperature and time intervals (104), iii. as a result of the holding time, taking it from the incubation device (8) as ready- to-use solid plasma (9) to be used as filling material (105).
2. A method of obtaining a solid plasma (100) according to claim 1 , characterized in that it performs the dissociation of plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of a polyester micro filter (5).
3. A method of obtaining a solid plasma (100) according to claim 1 , characterized in that ii. temperature and time intervals mentioned in the process step are 5 minutes in 70 eC, 7 minutes in 90 eC and 5 minutes in 5 eC.
PCT/TR2020/050560 2019-07-09 2020-07-01 Method for obtaining solid plasma as a filling material WO2021006839A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/10227 2019-07-09
TR2019/10227A TR201910227A2 (en) 2019-07-09 2019-07-09 METHOD OF OBTAINING SOLID PLASMA AS A FILLING MATERIAL

Publications (1)

Publication Number Publication Date
WO2021006839A1 true WO2021006839A1 (en) 2021-01-14

Family

ID=67901116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/050560 WO2021006839A1 (en) 2019-07-09 2020-07-01 Method for obtaining solid plasma as a filling material

Country Status (2)

Country Link
TR (1) TR201910227A2 (en)
WO (1) WO2021006839A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442114A2 (en) * 1990-02-12 1991-08-21 Pall Corporation Pre-storage filtration of platelets
WO1997022245A1 (en) * 1995-12-19 1997-06-26 Baxter International Inc. Systems and methods for removing free and entrained contaminants in plasma
WO2014126931A1 (en) * 2013-02-15 2014-08-21 Victor Steven Stable platelet- rich-plasma compositions and methods of use
CN107198893A (en) * 2017-07-01 2017-09-26 张方亮 Leucocyte-removing PRP preparation method
WO2018102909A1 (en) * 2016-12-06 2018-06-14 Antnor Limited Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
TR201513838A2 (en) * 2015-11-05 2020-10-21

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442114A2 (en) * 1990-02-12 1991-08-21 Pall Corporation Pre-storage filtration of platelets
WO1997022245A1 (en) * 1995-12-19 1997-06-26 Baxter International Inc. Systems and methods for removing free and entrained contaminants in plasma
WO2014126931A1 (en) * 2013-02-15 2014-08-21 Victor Steven Stable platelet- rich-plasma compositions and methods of use
TR201513838A2 (en) * 2015-11-05 2020-10-21
WO2018102909A1 (en) * 2016-12-06 2018-06-14 Antnor Limited Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
CN107198893A (en) * 2017-07-01 2017-09-26 张方亮 Leucocyte-removing PRP preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ETULAIN JULIA, MENA HEBE A., MEISS ROBERTO P., FRECHTEL GUSTAVO, GUTT SUSANA, NEGROTTO SOLEDAD, SCHATTNER MIRTA: "An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties", SCIENTIFIC REPORTS, vol. 8, no. 1513, 24 January 2018 (2018-01-24), pages 1 - 15, XP055785605 *

Also Published As

Publication number Publication date
TR201910227A2 (en) 2019-07-22

Similar Documents

Publication Publication Date Title
Epstein Jr Molecular genetics of epidermolysis bullosa
Delamare The lymphatics
Marks et al. Human dermal microvascular endothelial cells: an improved method for tissue culture and a description of some singular properties in culture
Madurantakam et al. Characterization of leukocyte-platelet rich fibrin, a novel biomaterial
JPH02503202A (en) Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels
JP2004500026A (en) Autologous thrombin
JP2004500026A5 (en)
CN102625689A (en) Method and composition for restoration of age-related tissue loss in the face or selected areas of the body
Abraham et al. Directing neuronal outgrowth and network formation of rat cortical neurons by cyclic substrate stretch
KR20120129779A (en) Methods for Activating Platelet by Applying Capillary Stresses
CN104173252B (en) A kind of biological beauty preparation of the cell containing autologous substrate
Machado et al. A simple double-spin closed method for preparing platelet-rich plasma
WO2021006839A1 (en) Method for obtaining solid plasma as a filling material
MacNeal et al. The finer vascular channels of the spleen
Marczynski et al. Advances in mucin biopolymer research: Purification, characterization, and applications
EP3313293A1 (en) Wearable device and method for collecting ocular fluid
MX2010010251A (en) Kit for collecting blood, preferably peripheral blood, for the production of stem cells.
Shetty et al. Comparative evaluation of efficacy of platelet-Rich Fibrin and hank’s balanced salt solution as a storage medium for avulsed teeth: An in vitro study
Slípka et al. Outlines of histology
CN104911140B (en) A kind of external glial scars form model and its construction method and application
CN108030914A (en) A kind of Matrigel raw material and preparation method and application
Eliason et al. Proliferation of vascular endothelial cells stimulated in vitro by corneal epithelium.
RU2582948C1 (en) Method for soft tissue augmentation by means of heat-processed platelet-rich autoplasma
Hasan et al. Platelet rich plasma (PRP) treatment: A view
KR20130131571A (en) Fat filler material and product using condensed single adipose cell(csac) and manufacturing method of it

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20837162

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20837162

Country of ref document: EP

Kind code of ref document: A1